← Eichor
Condition: Steroid Refractory Gvhd Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Steroid Refractory Gvhd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute
Phase 2 · 11 location(s) · ReAlta Life Sciences, Inc. · NCT06343792A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
NA · 1 location(s) · Anhui Provincial Hospital · NCT06321198Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07364617Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Phase 1 · 1 location(s) · Stefanie Sarantopoulos, MD, PhD. · NCT06233110Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
EARLY_Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06920199Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07184853Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05327023Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Phase 2 · 1 location(s) · Tata Memorial Centre · NCT07708987Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory A
EARLY_Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04744116Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available The
Phase 3 · 42 location(s) · medac GmbH · NCT04629833Universal CNK-UT Therapy for Refractory aGVHD
Phase 1 · 2 location(s) · First Affiliated Hospital of Zhejiang University · NCT06750133Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Dise
Phase 4 · 17 location(s) · Novartis Pharmaceuticals · NCT06462469Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
Phase 1 · 1 location(s) · Fujian Medical University · NCT06568328Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT02918188Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantat
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07572669Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Phase 1 · 1 location(s) · Leslie Kean · NCT06991361A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil
Phase 3 · 30 location(s) · Incyte Corporation · NCT06615050
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.